Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Journal of Experimental Hematology ; (6): 1574-1578, 2023.
Article in Chinese | WPRIM | ID: wpr-1010008

ABSTRACT

Daratumumab is the first CD38 monoclonal antibody drug approved for the treatment of patients with multiple myeloma. It can bind to CD38 expressed by tumor cells, inhibit tumor cell growth and induce myeloma cell apoptosis through a variety of immune-related mechanisms. Meanwhile, CD38 is also expressed in other cells, including regulatory T cells, regulatory B cells and myeloid-derived suppressor cells, which provides a theoretical basis for the treatment of hematological tumor diseases other than non-multiple myeloma diseases. This article reviews the research progress and application of this part.


Subject(s)
Humans , Multiple Myeloma/pathology , ADP-ribosyl Cyclase 1 , Antibodies, Monoclonal/pharmacology , Hematologic Neoplasms/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL